Please assess the completion status of the following clinical trial:

Trial Title: Danhong Injection in the Treatment of Chronic Stable Angina

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male inpatients.~* Age: 18 - 70 years.~* Patients with clinical diagnosis of chronic stable angina and must meet one of the following conditions:1）Patients who have a history of myocardial infarction and ST-T changes;2）Stenosis of more than 50% in at least one major epicardial coronary artery shown by Coronary Angiograph or CT Angiography; 3）Patients with coronary heart disease were determined by radionuclide angiocardiography.~* Clinical diagnosis of Xueyu Zheng (Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales of Xueyu Zheng in angina ≥ 15. The Chinese medicine symptoms scales of Xueyu Zheng is defined as following (1)chest pain-10, (2)chest distress-10, (3) palpitation-5, (4)purple or dark lip-5, (5) purple or dark tongue-5, (6) unsmooth pulse-5.~* Patients with moderate angina pectoris (The definition of moderate angina pectoris  is in accordance with the Canadian Cardiovascular Society (CCS) grading of angina pectoris,which be classified to II or III.~* Patient is willing to participate voluntarily and to sign a written patient informed consent.~Exclusion Criteria:~* Woman with pregnancy, lactation or positive result of pregnancy test, or woman who is under menstrual period.~* Woman who disagree with contraception during treatment period~* Patients with severe complications that would make the condition more complicated assessed by the investigator, including liver or renal dysfunction, severe cardiopulmonary dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, a history of epilepsy or cerebral hemorrhage .~* Patients who were angina-free during the run-in period without taking any drug.~* Patients with myocardial infarction or Canadian Cardiovascular Society (CCS) grading of angina pectoris class IV within the preceding 3 months~* Patients with chest pain caused by other disease (e.g., acute myocardial infarction，severe neurosis，menopausal syndrome，hyperthyroidism).~* Patients with history of drug-induced bleeding or history of bleeding caused by warfarin.~* Patients with history of hematopoietic system diseases.~* Patients who had surgery within the past 4 weeks and have hemorrhagic tendency.~* Patients who is participating in other trials or has been participated in other trials in recent 3 months.~* Patients with history of allergy or suspected allergic to the drug.~* Patients who were suspected addicted into alcohol or drug abuse in the past 2 years.~* Patients with mental disorder.~* Patients who were unable to participate in the study as judged by investigator.~* Patients who were family members or relatives of the research center staffs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Danhong injection (Type: EXPERIMENTAL): Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).